Market Intelligence, Clinical Progress, and High-Purity Reagents for Cancer Metabolism and Ophthalmology Research.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for LSS drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | LSS Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 or Insect cell expressed for native folding. |
View LSS Products |
| Gene Delivery | LSS Promise-ORF / Lentivirus Full-length ORF for stable cell line generation and overexpression assays. |
View LSS Products |
| Benchmark Ab | Anti-LSS Antibody (Research Grade Control) Recombinant antibody for target verification, Western Blot, and IHC. |
View LSS Products |
| Validator | LSS siRNA Set For specific gene knockdown and functional validation. |
View LSS Products |
| Related Target A | SQLE (Squalene Epoxidase) Upstream enzyme in the cholesterol biosynthesis pathway; key for synergistic lipid metabolism studies. |
View SQLE Products |
| Related Target B | DHCR7 (7-Dehydrocholesterol Reductase) Downstream enzyme in the cholesterol pathway; critical for evaluating bypass resistance mechanisms. |
View DHCR7 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Membrane association makes purification of active, soluble LSS highly challenging. | Optimized detergent-solubilized full-length or soluble domain constructs, sequence verified and purified to >95%. |
| Selectivity profiling against other sterol-modifying enzymes. | Comprehensive pathway panel (SQLE, DHCR7) available, strictly verified by mass spectrometry. |
| Lack of reliable positive controls for cellular assays. | Sequence-verified research-grade control antibodies and validated siRNA sets included in the catalog. |
| False positives in high-throughput small molecule screening. | Validated siRNA knockout/knockdown reagents provided for target-specificity confirmation. |
Live LSS R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of LSS (Lanosterol Synthase) is gaining traction as oncology and ophthalmology pipelines seek novel metabolic nodes. In cancer, LSS resides at a critical juncture of the mevalonate pathway, where its inhibition disrupts cholesterol homeostasis, selectively inducing cell death in cholesterol-dependent tumors such as breast, prostate, and colorectal cancers.
The race for LSS therapeutics is intensifying, with major players shifting focus from traditional systemic metabolic regulators to highly targeted small molecule inhibitors. As first-generation therapies reach the clinic, the next wave of R&D is targeting combination regimens to overcome bypass resistance and exploiting the molecular chaperone-like role of LSS in cataract prevention.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule | Academic Institutes, Biotech Startups | Solid Tumors (Breast, Colorectal) | Enzymatic Inhibition Assay (Need high-purity, natively folded LSS protein) |
| Small Molecule | Ophthalmic Biotechs | Congenital & Age-related Cataracts | Protein-Protein Interaction & Aggregation Assays (Need stable recombinant LSS) |
| RNAi / Gene Therapy | Preclinical Research Labs | Hypercholesterolemia, Metabolic Disorders | Knockdown Verification (Need high-specificity LSS siRNA and Lentivirus) |